Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
22 Octubre 2020 - 6:00AM
Business Wire
Study shows alopecia areata carries a
considerable psychosocial burden in patients
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that the Journal of Investigative Dermatology published results
from a survey designed to understand the burden and everyday
experience for patients living with moderate-to-severe alopecia
areata. The survey was conducted by the National Alopecia Areata
Foundation (NAAF) and the published results were authored by four
leading medical experts in dermatology, with funding for the study
provided by Concert Pharmaceuticals.
“The impact of alopecia areata extends beyond cosmetic concerns
and carries a considerable psychosocial burden for patients,”
stated lead author of the publication, Natasha Mesinkovska, MD,
PhD, Department of Dermatology, School of Medicine, University of
California, Irvine. “Based on the survey responses, there is an
important medical need for treatments to regrow hair which, in
turn, can have positive psychosocial impact on patients. We are
hopeful that we can move away from complacency about alopecia
areata and enter an era of more effective treatment.”
Key findings of the survey show that patients with alopecia
areata suffer significantly increased burden of illness
including:
- Alopecia areata has a negative impact on many aspects of daily
life, extending far beyond cosmetic concerns. Of 17 reported
comorbidities, anxiety and depression were the most prevalent.
- The significant psychosocial impact of alopecia areata on daily
life, with self-esteem or confidence impacting daily life the most,
did not abate over time.
- Alopecia areata can negatively redirect the course of a
patient’s life, culminating in unfulfilled professional and
academic aspirations as well as diminished expectations for
relationships and family life. Nearly two-thirds of respondents
indicated they had made different major life decisions (regarding
relationships, education or career) as a result of alopecia
areata.
- Patients reported a range of physical symptoms and
complications associated with alopecia areata, including
sensitivity to temperature and light, increased susceptibility to
sunburn, nail splitting, dryness and irritation in eyes and nose,
and inability to keep sweat and debris out of eyes.
- Hair loss concealment techniques and treatments were considered
unsatisfactory to patients and imposed a significant time and
financial burden. Hair loss was closely linked to a sense of
changing self-identity and, for many respondents, getting used to
an altered appearance was described as devastating and emotionally
draining.
About the Study
An online survey was completed by 216 eligible patients with
alopecia areata. Patients had a median disease duration of 13 years
with alopecia areata and most patients self-reported their hair
loss as being severe, with hair loss affecting more than one-third
of their scalp. The 25-item survey consisted of 4 sections: (i)
clinical severity and symptoms, (ii) impact on daily living and
activities, (iii) financial and treatment burden, and (iv)
demographics. Most survey respondents reported at least one
comorbidity; the most common being anxiety and depression. Other
common comorbidities included allergic rhinitis, thyroid disease,
atopic dermatitis and asthma.
The journal article, entitled “Burden of Illness in Alopecia
Areata: A Cross-Sectional Online Survey Study,” is available online
at:
https://www.jidsponline.org/article/S1087-0024(20)30017-4/fulltext
About Alopecia Areata
Alopecia areata is an autoimmune disease in which the immune
system attacks hair follicles, resulting in partial or complete
loss of hair on the scalp and body. Alopecia areata may affect up
to 700,000 Americans at any given time1. The scalp is the most
commonly affected area, but any hair-bearing site can be affected
alone or together with the scalp. Onset of the disease can occur
throughout life and affects both women and men. Alopecia areata can
be associated with serious psychological consequences, including
anxiety and depression. There are currently no drugs approved by
the Food and Drug Administration (FDA) for the treatment of
alopecia areata.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to treat
serious diseases and address unmet patient needs. The Company’s
approach starts with previously studied compounds, including
approved drugs, in which deuterium substitution has the potential
to enhance clinical safety, tolerability or efficacy. Concert’s
pipeline of innovative medicines targets autoimmune diseases and
central nervous systems (CNS) disorders. For more information
please visit www.concertpharma.com or follow us on Twitter at
@ConcertPharma or on LinkedIn.
1 Benigno M. Clinical, Cosmetic and Investigational Dermatology
2020
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201022005080/en/
Justine E. Koenigsberg (Investors) Concert Pharmaceuticals, Inc.
(781) 674-5284 ir@concertpharma.com
Kathryn Morris (media) The Yates Network (914) 204-6412
kathryn@theyatesnetwork.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024